Just the Facts Imugene receives Orphan Drug Designation for VAXINIA from FDA - Proactive Investors USA
| IMU Stock | 0.04 0 5.13% |
Slightly above 61% of Imugene's investor base is looking to short. The analysis of the overall investor sentiment regarding Imugene suggests that many traders are alarmed. Imugene's investing sentiment can be driven by a variety of factors including economic data, Imugene's earnings reports, geopolitical events, and overall market trends.
Imugene |
Just the Facts Imugene receives Orphan Drug Designation for VAXINIA from FDA Proactive Investors USA
Read at news.google.com
 |
Imugene Fundamental Analysis
We analyze Imugene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Imugene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Imugene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Imugene is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Imugene Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Imugene stock to make a market-neutral strategy. Peer analysis of Imugene could also be used in its relative valuation, which is a method of valuing Imugene by comparing valuation metrics with similar companies.
Peers
Imugene Related Equities
| CBA | Commonwealth Bank | 1.57 | ||||
| ANZ | Australia | 0.79 | ||||
| AN3PI | ANZ Group | 0.55 | ||||
| AN3PJ | ANZ Group | 0.53 | ||||
| CBAPJ | Commonwealth Bank | 0.1 | ||||
| CBAPM | Commonwealth Bank | 0.09 | ||||
| ATM | Aneka Tambang | 0.00 | ||||
| CBAPI | Commonwealth Bank | 0.17 |
Additional Tools for Imugene Stock Analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.